3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
11
Phase EARLY_PHASE1
2
Phase 3
2
Phase 2
2
Phase 1
2
Phase 4
1
Status
Completed
2
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Gynecologic
1
Gastrointestinal
1
Conditions
Squamous Intraepithelial Lesions
1
Papillomavirus Infections
1
Mucositis
1
Hematologic Neoplasms
1
HIV Infections
1
Anus Neoplasms
1
Acquired Immunodeficiency Syndrome
1
Interventions
Cyclophosphamide
299
Cisplatin
298
Paclitaxel
257
Radiotherapy
255
Fluorouracil
234
Carboplatin
234
Docetaxel
230
Doxorubicin
216
Dexamethasone
166
Gemcitabine
156
Vincristine
147
Etoposide
136
Leucovorin
133
Capecitabine
129
Bevacizumab
129
Prednisone
125
Rituximab
118
Methotrexate
118
Cytarabine
110
Filgrastim
99
Trastuzumab
97
Oxaliplatin
96
pembrolizumab
83
Pemetrexed
73
Epirubicin
70
Tamoxifen
69
Drug Therapy
69
Irinotecan
65
Granulocyte Colony-Stimulating Factor
60
Daunorubicin
58
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Completed
×
Laser Therapy
×
Clear all
NCT02135419
2024-07-26
ANCHOR
AIDS Malignancy Consortium
Phase 3
Completed
4,446 enrolled
13 charts
NCT02696408
2020-01-29
STOP MUCITES
Institut de Cancérologie de la Loire
Phase 3
Completed
234 enrolled